Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations
Pediatric Blood & Cancer · 2026-07 · 73 (7)
DOI: 10.1002/1545-5017.70380 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 07.05.2026. Verfasst von Marie C Heider und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology and Non-Hodgkin Lymphoma Berlin-Frankfurt-Muenster Study Center, University Hospital Muenster, Muenst…. Hauptthemen laut MEDLINE: Receptor, Notch1, Mutation, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Biomarkers, Tumor. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mildred-Scheel-Doctoral Program of the Deutsche Krebshilfe.
Abstract (Originalsprache)
In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within one spectrum. This review focuses on T‐LBL, summarizing shared and distinct clinical, pathological, and biological features in comparison to T‐ALL. We address diagnostic and staging challenges, and current limitations of clinical risk stratification. Biomarkers, such as genetic variants in NOTCH1 / FBXW7 , are discussed in the context of dynamic risk assessment. Particularly emphasizing the molecular landscape of T‐LBL and recurrent pathway alterations. NOTCH1 emerges as central determinant of disease biology. Activating NOTCH1 mutations (NOTCH1 mut ) are frequently associated with favorable outcomes and used for risk stratification in the ongoing trial LBL 2018 (EUCT number: 2023‐508101‐24‐00). NOTCH1 fusions resulting in excessive NOTCH1 signaling are associated with increased relapse incidences, suggesting that the intracellular amount of NOTCH1 differentiates between tumor suppressive versus tumor supportive activity. These findings are placed in the context of recently described NOTCH1 variants in T‐ALL, reported to similarly cause aberrant NOTCH1 activation. Future studies may consider incorporating detailed NOTCH1 status to understand disease dynamics and enhance therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology and Oncology and Non-Hodgkin Lymphoma Berlin-Frankfurt-Muenster Study Center, University Hospital Muenster, Muenster, Germany.
ORCID-Profile: Marie C Heider, Marcel Te Vrugt
Förderung
- Mildred-Scheel-Doctoral Program of the Deutsche Krebshilfe
Zitieren
APA
Heider, M. C., Alfert, A., Hotfilder, M., Burkardt, B., & Te Vrugt, M. (2026). Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations. Pediatric Blood & Cancer, 73(7). https://doi.org/10.1002/1545-5017.70380
Vancouver
Heider MC, Alfert A, Hotfilder M, Burkardt B, Te Vrugt M. Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations. Pediatric Blood & Cancer. 2026;73(7). doi:10.1002/1545-5017.70380
BibTeX
@article{Heider2026,
author = {Heider, Marie C and Alfert, Amelie and Hotfilder, Marc and Burkardt, Birgit and Te Vrugt, Marcel},
title = {Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {7},
doi = {10.1002/1545-5017.70380}
}
EUVIMED